Charles Whittaker, Oliver J Watson, Carlos Alvarez-Moreno, Nasikarn Angkasekwinai, Adhiratha Boonyasiri, Luis Carlos Triana, Duncan Chanda, Lantharita Charoenpong, Methee Chayakulkeeree, Graham S Cooke, Julio Croda, Zulma M Cucunubá, Bimandra A Djaafara, Cassia F Estofolete, Maria Eugenia Grillet, Nuno R Faria, Silvia Figueiredo Costa, David A Forero-Peña, Diana M Gibb, Anthony C Gordon, Raph L Hamers, Arran Hamlet, Vera Irawany, Anupop Jitmuang, Nukool Keurueangkul, Teresia Njoki Kimani, Margarita Lampo, Anna S Levin, Gustavo Lopardo, Rima Mustafa, Shevanthi Nayagam, Thundon Ngamprasertchai, Ng'ang'a Irene Hannah Njeri, Mauricio L Nogueira, Esteban Ortiz-Prado, Mauricio W Perroud, Andrew N Phillips, Panuwat Promsin, Ambar Qavi, Alison J Rodger, Ester C Sabino, Sorawat Sangkaew, Djayanti Sari, Rujipas Sirijatuphat, Andrei C Sposito, Pratthana Srisangthong, Hayley A Thompson, Zarir Udwadia, Sandra Valderrama-Beltrán, Peter Winskill, Azra C Ghani, Patrick G T Walker, Timothy B Hallett
BACKGROUND: The public health impact of the coronavirus disease 2019 (COVID-19) pandemic has motivated a rapid search for potential therapeutics, with some key successes. However, the potential impact of different treatments, and consequently research and procurement priorities, have not been clear. METHODS: Using a mathematical model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission, COVID-19 disease and clinical care, we explore the public-health impact of different potential therapeutics, under a range of scenarios varying healthcare capacity, epidemic trajectories; and drug efficacy in the absence of supportive care...
August 24, 2022: Clinical Infectious Diseases